Open in interactive viewer → charts, metric popovers & call review

Verbio's Blowout Quarter Is a Spread Story — If You Believe the CEO Over the Tape

A €76 million Q1, guidance nudged to the top of the range, and a management team spending the call insisting this is neither an oil trade nor a run-rate
VBK.DE · Earnings Call · 2026-11-12

The quarter management won't let you annualize

Verbio opened fiscal 2026/27 with the kind of print that normally gets a victory lap: group EBITDA of €76.1 million against €15.4 million a year earlier, operating cash flow swinging from −€17.3 million to +€34.1 million, free cash flow from −€37.8 million to +€13.5 million, and net debt trimmed from €91.5 million at the June year-end to €83.1 million. Management duly lifted full-year expectations to the top of its €210–250 million band. And then proceeded to spend much of the call explaining why investors should not extrapolate any of it.

That is the central tension of this report. The quarter was real, the margin expansion was real, but almost every driver is either seasonal, market-spread-driven, or deferred. CFO Olaf Troeber put the caveat plainly: “the first quarter performance should not be seen as indicative for the full year run rate” — Olaf Troeber, Chief Financial Officer (CFO) · 2026-11-12. The company is asking you to celebrate a blowout while penciling it back in.

The CEO versus the price tape

Beneath the financials sits a strategic argument that CEO Claus Sauter has now made on consecutive calls — that Verbio is mis-priced by anyone who treats it as a crude derivative. The biodiesel segment did the heavy lifting this quarter: sales up to €306 million from €280 million, segment EBITDA from €32 million to €51 million, driven by biodiesel prices rising while rapeseed oil softened, plus opportunistic feedstock bought below market. None of that required high oil. So Sauter took direct aim at the misreading:

This does not mean that our earnings simply follow the oil price... Biofuels have their own markets. Their prices depend on supply and demand and are closely linked to their feedstock markets... high fossil fuel prices will support demand for biofuels, but they do not directly determine Verbio's margin or EBITDA.

Claus Sauter, Chief Executive Officer (CEO) · 2026-11-12

It is a repeat performance. In September he used almost the same words: “There is no correlation even if it looks like it. So our feedstock is mainly rapeseed oil.” — Claus Sauter, CEO · 2026-09-24 The market persists in trading VBK against the fossil tape; the CEO persists in pointing at the rapeseed methyl ester spread and the carbon-compliance value his molecules carry instead. The Q1 evidence actually supports him — and that is the gap worth watching.

What tightened the molecule market this quarter is a genuinely fresh theme for this company: low water on the Rhine. It restricted rapeseed crushing, constrained RME availability, and — as a bonus — made physical greenhouse-gas compliance harder for participants dependent on river logistics. Combined with the looming disappearance of palm oil-linked feedstocks from the 2027 compliance pool, it explains why compliant producers can realize margins above benchmark spreads.

A regulatory re-rating hiding in the fine print

The more durable story is regulatory, and it moved forward this quarter on two fronts. First, Germany is finally acting on fraud: with the Vertrauensschutz protection lapsing in January 2027, fuels carrying fraudulent sustainability documents can be excluded from the greenhouse-gas quota system. Sauter framed this as tougher action against falsely declared biofuels, and he expects customers to prize reliable, compliant supply chains in negotiations — a potential support for both demand and commercial terms.

Second, the EU post-2035 framework is crystallizing: a Parliament compromise now recognizes vehicles running only on eligible renewable fuels as zero-emission, and Sauter's refrain — “the problem is not the combustion engine. The problem is the fuel” — Claus Sauter, Chief Executive Officer (CEO) · 2026-11-12 — is aimed squarely at the combustion engine debate. Add a quota obligation rising from 12% to 17.5% in 2027 and the structural demand story for his molecules strengthens.

But here is the friction the call did not fully resolve. The single biggest swing factor in guidance is the quota price, and it is softening precisely as guidance goes up. Troeber flagged the pressure: “Since the end of the quarter and with the start of the annual tender season, quota prices have come under some pressure. So we remain cautious on the future further price development.” — Olaf Troeber, Chief Financial Officer (CFO) · 2026-11-12 Sauter guided to €400–500 per tonne versus the €420–440 he cited in September. So the company is raising the EBITDA outlook while the highest-leverage variable drifts lower — that is a tension, not a consensus.

What's deliberately missing

Two upside levers were explicitly left out of numbers. The first is the U.S. 45Z value — the carbon-intensity-linked tax credit that peers across the biofuel complex are already discussing. It has now been deferred three calls running. In September management said it was not in the plan; this quarter Sauter was again disciplined: “we cannot take something into our guidance. There will be something, but we have to wait until we really, really have the final guidance.” — Claus Sauter, Chief Executive Officer (CEO) · 2026-11-12 The final rules arrive in December, which is also when term contracts for the second half get negotiated — a single month carrying a lot of the year's uncertainty.

The second is ethenolysis. The Bitterfeld specialty-chemicals plant is still commissioning, with first saleable volumes expected around November–December, but management capped expectations hard: “don't expect too much from this ethanol -- of ethenolysis. This is, for us, a project for the future” — Claus Sauter, Chief Executive Officer (CEO) · 2026-11-12. That echoes February's warning of no meaningful contribution in the next business year. The strategic prize is real — moving RME out of fuel and into higher-margin chemicals — but it is years away, not a 2027 earnings line.

India rounds out the deferred-optionality list: the GAIL joint venture is progressing and the compressed-biogas market is "taking off," but there are still no disclosed numbers. The through-line is consistent — Verbio is stacking up real, structural catalysts (fraud enforcement, RED III, 45Z, chemicals, India) while reporting a quarter whose profit came almost entirely from a favorable spread and cheap feedstock that management itself declines to promise will persist.

The honest read: this is a spread-driven beat dressed in a regulatory-growth narrative, and the investment case turns on whether the regulatory side earns a re-rating before the spread side normalizes. The CEO is betting the market eventually prices the molecules, not the oil.